Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00755222 · ClinicalTrials.gov registry record · Phase 2
The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease
A Phase 2 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 147
- Enrollment target
NCT00755222: Completed Phase 2 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
NCT00755222 is a Phase 2 study that has completed, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 147 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00755222, a Phase 2 study, has completed, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 147 participants
- Enrollment target
Study Summary
This study evaluated the safety and effectiveness of AA4500 in improving the impact of Peyronie's disease on quality of life and improving penile curvature in men with Peyronie's disease
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL AA4500
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2008-08 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00755222
The ClinicalTrials.gov registry entry for NCT00755222 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 147 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endo USA Inc., a Keenova Therapeutics Company, which has 61 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00755222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00755222 about?
NCT00755222 is a clinical study titled "The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease". This study evaluated the safety and effectiveness of AA4500 in improving the impact of Peyronie's disease on quality of life and improving penile curvature in men with Peyronie's disease
What is the current status of trial NCT00755222?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 147 participants. The study started on 2008-08. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00755222?
The interventions under investigation include: Placebo (BIOLOGICAL), AA4500 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00755222?
This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.